ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 899,83
0,77%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) Actualités

AUPH Aurinia Pharmaceuticals Inc

4,9001
0,0301 (0,62%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Aurinia Pharmaceuticals Inc AUPH NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0301 0,62% 4,9001 06:00:07
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,89 4,86 5,01 4,91 4,87
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/4/202416:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15/4/202412:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09/4/202412:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
07/3/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:10EDGAR2Form 8-K - Current report
29/2/202414:30BWAurinia Receives Exemptive Relief from Canadian Securities..
27/2/202414:30BWAurinia to Participate in Upcoming Investor Healthcare..
22/2/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
15/2/202412:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202412:06EDGAR2Form 8-K - Current report
15/2/202412:00BWAurinia Discloses 2023 Year-End Financial and Operational..
14/2/202421:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202414:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
05/1/202412:02EDGAR2Form 8-K - Current report
05/1/202412:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
20/12/202312:00BWAurinia Submits IND Application to US Food & Drug..
13/11/202312:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
07/11/202316:30BWAurinia Presents Breadth of Data from AURORA Clinical..
02/11/202323:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
02/11/202311:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202311:01EDGAR2Form 8-K - Current report
02/11/202311:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
26/10/202321:00BWAurinia Response in Support of 2023 Updated EULAR..
19/10/202316:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..
19/10/202312:00BWAurinia Pharmaceuticals to Release Third Quarter Financial..
13/10/202318:00BWAurinia Pharmaceuticals Announces Presentations at American..
22/9/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202322:06EDGAR2Form 8-K - Current report
21/9/202312:00BWAurinia Board of Directors Appoints Dr. Robert T. Foster as..
21/8/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202322:11EDGAR2Form 8-K - Current report
21/8/202312:00BWAurinia Appoints Two New Board Directors with Deep..
03/8/202312:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202312:03EDGAR2Form 8-K - Current report
03/8/202312:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
20/7/202312:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
19/7/202318:05BWLong Term Phase 3 Data Published in Arthritis & Rheumatology..
06/7/202314:33EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
03/7/202312:06EDGAR2Form 8-K - Current report
29/6/202322:05BWAurinia Board of Directors Announces Exploration of..
20/6/202315:00BWAurinia Showcases Three Oral Presentations for LUPKYNIS®..
01/6/202315:00BWLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal..

Dernières Valeurs Consultées

NASDAQ
AUPH
Aurinia Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés